236 results
Page 5 of 12
POS AM
qmfb337c1h3mrut8kyvb
24 Mar 21
Prospectus update (post-effective amendment)
9:17am
8-K
EX-99.1
midmpfq7kc39
23 Mar 21
GeoVax Reports 2020 Year-End Financial Results
4:35pm
8-K
EX-99.1
jse28qu
11 Feb 21
GeoVax Announces Closing of $10.3 Million Bought Deal Offering
2:35pm
8-K
EX-99.1
v3j1ilj6cjx6k 2sq6s
11 Feb 21
GeoVax Announces Pricing of $9.0 Million Bought Deal Offering
9:21am
424B5
zsn0ec3454
11 Feb 21
Prospectus supplement for primary offering
9:17am
8-K
EX-10.1
3bc 0x5cq
30 Nov 20
GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development
5:18pm
8-K
EX-99.1
xtbq559cz3cqq72gxh
30 Nov 20
GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development
5:18pm
8-K
EX-99.1
8fvrf
5 Nov 20
GeoVax Reports 2020 Third Quarter Financial Results
5:18pm
424B3
22hyfgy fdfc
5 Nov 20
Prospectus supplement
5:17pm
8-K
EX-99.1
jqnyg2m40nl0xfna
26 Oct 20
GeoVax Announces License Agreement with NIH
5:28pm
8-K
EX-10.1
bxdwwd3z3p8fsa2gjg
26 Oct 20
GeoVax Announces License Agreement with NIH
5:28pm
8-K
EX-99.1
84tmbg
29 Sep 20
GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq
5:24pm
424B4
zxcps x9o86
28 Sep 20
Prospectus supplement with pricing info
4:56pm
8-K
EX-99.1
3upunpbseu2 qe25a
25 Sep 20
Entry into a Material Definitive Agreement
5:25pm